Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.

European journal of clinical pharmacology - 1 Jan 2000

Raslová K, Dobiásová M, Nagyová A, Fábry R, Rauchová H, Dusinská M

Abstract excerpt

OBJECTIVES: This study was conducted to examine a complex effect of ciprofibrate therapy in patients with atherogenic lipoprotein phenotype. METHODS: Effects of ciprofibrate were studied on HDL subpopulations, HDL ability to esterify cholesterol (FER(HDL)), susceptibility of LDL to oxidation as well as on in vivo oxidative DNA damage in peripheral lymphocytes, measured as strand breaks (SBs) by the comet assay....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arteriosclerosis
Share to DNA Damage

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Kinetics

Share to Lipoproteins

Share to Lipoproteins, LDL

Share to Lymphocytes

Share to Oxidation-Reduction

Share to Phenotype

Source

Identifiers

PMID: 9923570
DOI: 10.1007/s002280050537

Genes

FER

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.PMID 9923570Read ↗

Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.Semantic proximity Read ↗

Overview of fenofibrate.Semantic proximity Read ↗

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.Semantic proximity Read ↗

Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency.Semantic proximity Read ↗

Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.Semantic proximity Read ↗

A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients.Semantic proximity Read ↗

Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants.Semantic proximity Read ↗

A new mathematical model to quantify and characterize the response to pro- and anti-oxidants of the copper-induced oxidation of LDL assay. A tool for examination of potential preventive compounds and clinical risk predictionSemantic proximity Read ↗

Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-->R genetic polymorphism.Semantic proximity Read ↗

Fibrate treatment and prevalence risk of mild hyperhomocysteinaemia in clinical coronary heart disease patients.Semantic proximity Read ↗

The effect of HDL-bound and free PON1 on copper-induced LDL oxidation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.